Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Celldex Therapeutics Inc (CLDX)
NASDAQ:CLDX
Celldex (CLDX) Stock Price & Analysis
975 Followers
CLDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$22.11 - $53.18
Previous Close$41.65
Volume911.67K
Average Volume (3M)932.32K
Market Cap
$2.75B
Enterprise Value$2.51B
Total Cash (Recent Filing)$235.35M
Total Debt (Recent Filing)$2.85M
Price to Earnings (P/E)-14.3
Beta1.31
Next Earnings
Aug 07, 2024EPS Estimate
-$0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.91
Shares Outstanding55,900,679
10 Day Avg. Volume581,540
30 Day Avg. Volume932,321
Standard Deviation0.53
R-Squared0.03
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)5.92
Price to Sales (P/S)987.81
Price to Cash Flow (P/CF)-18.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue575.64
Enterprise Value/Gross Profit1.07K
Enterprise Value/Ebitda-28.38
Forecast
1Y Price Target
$69.17Price Target Upside63.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Celldex News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPhase 3 CSU studies for barzo are expected to begin, reflecting positive momentum in the drug's development.
Drug EfficacyBarzolvolimab shows promising efficacy and safety in treatment of chronic spontaneous urticaria, setting the stage for becoming a therapy of choice.
Financial StabilityCelldex ended the year financially strong, with significant cash reserves to fund ongoing operations and research.
Bears Say
Drug SafetyBarzo's safety will be the major investor focus for the AAAAI presentation, presenting a bit of risk for its acceptance in the market.
Healthcare CostsUnchecked chronic urticaria negatively impacts long-term patient quality of life outcomes and is associated with significant adverse health care costs.
Market CompetitionUrticaria space is becoming increasingly crowded, indicating rising competition for Celldex's barzo.
---
Ownership Overview
18.40% Insiders
29.63% Mutual Funds
14.88% Other Institutional Investors
37.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLDX FAQ
What was Celldex Therapeutics Inc’s price range in the past 12 months?
Celldex Therapeutics Inc lowest stock price was $22.11 and its highest was $53.18 in the past 12 months.
What is Celldex Therapeutics Inc’s market cap?
Currently, no data Available
When is Celldex Therapeutics Inc’s upcoming earnings report date?
Celldex Therapeutics Inc’s upcoming earnings report date is Aug 07, 2024 which is in 90 days.
How were Celldex Therapeutics Inc’s earnings last quarter?
Celldex Therapeutics Inc released its earnings results on May 06, 2024. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.693 by $0.133.
Is Celldex Therapeutics Inc overvalued?
According to Wall Street analysts Celldex Therapeutics Inc’s price is currently Undervalued.
Does Celldex Therapeutics Inc pay dividends?
Celldex Therapeutics Inc does not currently pay dividends.
What is Celldex Therapeutics Inc’s EPS estimate?
Celldex Therapeutics Inc’s EPS estimate is -$0.59.
How many shares outstanding does Celldex Therapeutics Inc have?
Celldex Therapeutics Inc has 65,910,545 shares outstanding.
What happened to Celldex Therapeutics Inc’s price movement after its last earnings report?
Celldex Therapeutics Inc reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.693. Following the earnings report the stock price went up 1.345%.
Which hedge fund is a major shareholder of Celldex Therapeutics Inc?
Among the largest hedge funds holding Celldex Therapeutics Inc’s share is Woodline Partners LP. It holds Celldex Therapeutics Inc’s shares valued at 15M.
---
Celldex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$69.17 (63.87% Upside)
$69.17 (63.87% Upside)
Blogger Sentiment
Bullish
CLDX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 528.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $93.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.15%
12-Months-Change
Fundamentals
Return on Equity
-37.45%
Trailing 12-Months
Asset Growth
32.00%
Trailing 12-Months
Company Description
Celldex Therapeutics Inc
Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
---
CLDX Stock 12 Month Forecast
Average Price Target
$69.17
▲(63.87% Upside)
Technical Analysis
Best Analysts Covering CLDX
1 Year
1 Year Success Rate
10/11 ratings generated profit
1 Year Average Return
+21.02%
reiterated a buy rating 2 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +21.02% per trade.
---